Back to top
more

Inotiv (NOTV)

(Delayed Data from NSDQ)

$1.92 USD

1.92
312,220

-0.09 (-4.48%)

Updated Aug 1, 2025 04:00 PM ET

After-Market: $1.92 0.00 (0.00%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value A Growth C Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 32% (79 out of 246)

Industry: Medical - Drugs

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Inotiv, Inc. (NOTV) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

Inotiv (NOTV) delivered earnings and revenue surprises of 25% and 3.41%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Bioventus (BVS) Q1 Earnings and Revenues Surpass Estimates

by Zacks Equity Research

Bioventus (BVS) delivered earnings and revenue surprises of 33.33% and 2.72%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Will Nektar Therapeutics (NKTR) Report Negative Q1 Earnings? What You Should Know

by Zacks Equity Research

Nektar (NKTR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

Inotiv, Inc. (NOTV) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

by Zacks Equity Research

Inotiv (NOTV) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

Inotiv, Inc. (NOTV) Reports Q3 Loss, Lags Revenue Estimates

by Zacks Equity Research

Inotiv (NOTV) delivered earnings and revenue surprises of -122.22% and 14.51%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Crinetics Pharmaceuticals, Inc. (CRNX) Reports Q1 Loss, Misses Revenue Estimates

by Zacks Equity Research

Crinetics Pharmaceuticals (CRNX) delivered earnings and revenue surprises of -10.71% and 21.47%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Inotiv (NOTV) Is a Great Choice for 'Trend' Investors, Here's Why

by Zacks Equity Research

If you are looking for stocks that are well positioned to maintain their recent uptrend, Inotiv (NOTV) could be a great choice. It is one of the several stocks that passed through our "Recent Price Strength" screen.

Zacks Equity Research

Why Fast-paced Mover Inotiv (NOTV) Is a Great Choice for Value Investors

by Zacks Equity Research

If you are looking for stocks that have gained strong momentum recently but are still trading at reasonable prices, Inotiv (NOTV) could be a great choice. It is one of the several stocks that passed through our 'Fast-Paced Momentum at a Bargain' screen.

Zacks Equity Research

Is Inotiv (NOTV) a Great Value Stock Right Now?

by Zacks Equity Research

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Zacks Equity Research

Are Investors Undervaluing Collegium Pharmaceutical (COLL) Right Now?

by Zacks Equity Research

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Zacks Equity Research

Here's Why Momentum in Inotiv, Inc. (NOTV) Should Keep going

by Zacks Equity Research

Inotiv, Inc. (NOTV) could be a solid choice for shorter-term investors looking to capitalize on the recent price trend in fundamentally sound stocks. It is one of the many stocks that passed through our shorter-term trading strategy-based screen.

Zacks Equity Research

Inotiv, Inc. (NOTV) is a Great Momentum Stock: Should You Buy?

by Zacks Equity Research

Does Inotiv, Inc. (NOTV) have what it takes to be a top stock pick for momentum investors? Let's find out.

Zacks Equity Research

Despite Fast-paced Momentum, Inotiv, Inc. (NOTV) Is Still a Bargain Stock

by Zacks Equity Research

Inotiv, Inc. (NOTV) could be a great choice for investors looking to buy stocks that have gained strong momentum recently but are still trading at reasonable prices. It is one of the several stocks that made it through our 'Fast-Paced Momentum at a Bargain' screen.

Zacks Equity Research

Should Value Investors Buy Inotiv (NOTV) Stock?

by Zacks Equity Research

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Zacks Equity Research

Here's What Could Help Inotiv, Inc. (NOTV) Maintain Its Recent Price Strength

by Zacks Equity Research

Inotiv, Inc. (NOTV) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.

Zacks Equity Research

Inotiv, Inc. (NOTV) Is Attractively Priced Despite Fast-paced Momentum

by Zacks Equity Research

Inotiv, Inc. (NOTV) could be a great choice for investors looking to buy stocks that have gained strong momentum recently but are still trading at reasonable prices. It is one of the several stocks that made it through our 'Fast-Paced Momentum at a Bargain' screen.

Zacks Equity Research

Are Investors Undervaluing Inotiv (NOTV) Right Now?

by Zacks Equity Research

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Zacks Equity Research

Inotiv, Inc. (NOTV) Reports Q1 Loss, Lags Revenue Estimates

by Zacks Equity Research

Inotiv, Inc. (NOTV) delivered earnings and revenue surprises of -957.14% and 0.56%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

USANA Health Sciences (USNA) Q4 Earnings and Revenues Beat Estimates

by Zacks Equity Research

USANA Health (USNA) delivered earnings and revenue surprises of 67.31% and 6.96%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Inotiv, Inc. (NOTV) Shows Fast-paced Momentum But Is Still a Bargain Stock

by Zacks Equity Research

Inotiv, Inc. (NOTV) could be a great choice for investors looking to buy stocks that have gained strong momentum recently but are still trading at reasonable prices. It is one of the several stocks that made it through our 'Fast-Paced Momentum at a Bargain' screen.

Zacks Equity Research

Inotiv, Inc. (NOTV) Q3 Earnings Miss Estimates

by Zacks Equity Research

Inotiv, Inc. (NOTV) delivered earnings and revenue surprises of -73.08% and 6.56%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Century Therapeutics, Inc. (IPSC) Reports Q2 Loss, Misses Revenue Estimates

by Zacks Equity Research

Century Therapeutics, Inc. (IPSC) delivered earnings and revenue surprises of -3.70% and 93.58%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Ironwood Pharmaceuticals (IRWD) Q2 Earnings and Revenues Surpass Estimates

by Zacks Equity Research

Ironwood (IRWD) delivered earnings and revenue surprises of 24% and 3.79%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Adherex Technologies Inc. (FENC) Reports Q2 Loss, Lags Revenue Estimates

by Zacks Equity Research

Adherex Technologies Inc. (FENC) delivered earnings and revenue surprises of -16.67% and 17.12%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Corcept Therapeutics (CORT) Q2 Earnings and Revenues Surpass Estimates

by Zacks Equity Research

Corcept (CORT) delivered earnings and revenue surprises of 66.67% and 7.30%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?